scholarly journals Healthcare Resource Utilization and Healthcare costs of patients infected with the SARS-CoV-2 virus in a tertiary care public hospital: A cross-sectional study in Thailand

2020 ◽  
Author(s):  
Jirapong Leeyaphan ◽  
Charussri Leeyaphan ◽  
Patama Sutha ◽  
Suthira Taychakhoonavudh ◽  
Nattanichcha Kulthanachairojana
Keyword(s):  
Linear Regression ◽  
Resource Utilization ◽  
Healthcare Resource ◽  
Tertiary Care ◽  
Patient Characteristics ◽  
Healthcare Resource Utilization ◽  
Linear Regression Models ◽  
Cross Sectional ◽  
Personal Protection Equipment ◽  
Medication Costs

Abstract Background: Health care costs (HCCs) are a significant concern in developing countries. We investigated the healthcare resource utilization (HCRU) and HCCs for patients with COVID-19 concerning disease-severity and infection site.Methods: We reviewed the data from electronic medical records of COVID-19 patients. We used comorbidity conditions and patient characteristics as covariates. Analyses were conducted using simple linear regression and generalized linear regression models with a log–link and gamma distribution. Results: A total of 202 patients were confirmed to have a SARS-CoV-2 infection. Total costs per patient were USD 6,626 (USD 5,901–7,350). Personal protection equipment costs were the most significant cost for COVID-19 patients (USD 3,777). Mean medication costs per patient were USD 300 (USD 182–419). Patients with severe symptoms and a lower respiratory tract infection (LRI) had a higher cost and resource utilization value both before and after adjusting for covariates.Conclusions: COVID-19 patients with severe symptoms and LRI were associated with higher HCRU. length of stay, severe symptoms, and LRI were associated with a higher cost of treatment.

Healthcare Resource Utilization and Healthcare Costs of COVID-19 Patients in A Tertiary Care Public Hospital: A Retrospective Cohort Study in Thailand

2021 ◽  
Vol 104 (12) ◽  
pp. 1953-1958
Keyword(s):  
Linear Regression ◽  
Resource Utilization ◽  
Healthcare Costs ◽  
Healthcare Resource ◽  
Tertiary Care ◽  
Patient Characteristics ◽  
Healthcare Resource Utilization ◽  
Linear Regression Models ◽  
Personal Protection Equipment ◽  
Objective Health

Objective: Health care costs (HCCs) are a significant concern in developing countries. The authors investigated the healthcare resource utilization (HCRU) and HCCs for patients with COVID-19 based on disease severity and infection site. Materials and Methods: The authors reviewed data from the electronic medical records of COVID-19 patients admitted to the present study hospital between January 2020 and April 2020. The authors used comorbidities and patient characteristics as covariates. Analyses were conducted using simple linear regression and generalized linear regression models with a log-link and gamma distribution. Results: Two hundred two patients had confirmed SARS-CoV-2 infection. Total costs per patient were 6,626 USD (756 to 45,586). Personal protection equipment costs were the most significant cost for COVID-19 patients with a mean of 3,778 USD. The mean treatment cost per patient was 326 USD. Patients with severe symptoms and lower respiratory tract infection (LRI) had a higher cost and resource utilization value before and after adjusting for covariates. Conclusion: COVID-19 patients with severe symptoms and LRI had higher HCRU. Length of stay, severity of symptoms, and LRI were associated with higher cost of treatment. Keywords: SARS-CoV-2; COVID-19; Healthcare resource utilization; Healthcare costs; Thailand

scholarly journals Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study

2021 ◽  
Author(s):  
Celine Miyazaki ◽  
Yukata Ishii ◽  
Natalia M. Stelmaszuk
Keyword(s):  
Resource Utilization ◽  
Real World ◽  
Healthcare Resource ◽  
Patient Characteristics ◽  
Healthcare Resource Utilization ◽  
Systemic Steroid ◽  
Treatment Burden ◽  
Chi Square ◽  
Systemic Steroids ◽  
Chi Square Test

Abstract Introduction/objectives Since new consensus on polymyositis (PM) and dermatomyositis (DM) were released in Japan, an updated evidence on treatment landscape and PM/DM burden was essential. This study evaluates treatment burden and overall treatment cost of PM/DM-related inpatient and outpatient visits, treatments, and procedures/patient/year. Method This retrospective, observational study analyzed insurance claims from Japan Medical Data Center (JMDC) database. Patients with at least one PM/DM diagnosis/one dispensation of treatment between 1 January 2009 and 31 December 2019 were enrolled. Patient characteristics, treatment patterns and sequence, treatment choices, healthcare resource utilization (HCRU), and related costs were assessed. Chi-square test and linear regression model were used to assess impact of patient characteristics on treatment choice. Results Patients (836/4,961) receiving a relevant treatment were analyzed. Heart disease (35%), interstitial lung disease (27%), and diabetes mellitus (26%) were frequently identified as comorbidities. Concomitant dispensation of immunosuppressants and systemic steroids was largely found in first and second line of treatment (LoT) while systemic steroids remained as single dominant treatment across all LoTs. HCRU was very low for inpatient visits (0.68 [1.43]) or rehabilitation (4.74 [14.57]). The mean (SD) number of inpatient visits decreased from first (1.23 [2.32]) to third year (0.11 [0.54]). Total mean (SD) healthcare cost per patients per year was ¥ 3,815,912 (7,412,241), with overall drug dispensation compounding to 80% of total cost. Conclusions High concomitant immunosuppressant and systemic steroid prescriptions in first LoT recommend early optimal treatment to manage PM/DM. Although inpatient costs are low, outpatient dispensation costs increase overall economic burden. Key Points• Japan faces treatment challenges in the prognosis of polymyositis (PM) and dermatomyositis (DM) and thus, we assessed the real-world treatment landscape, practice, patterns, and healthcare resource utilization as an evidence to support healthcare outcome improvement and treatment burden reduction.• Systemic steroids were the dominant preferred choice of treatment, but it increases the overall cost of the treatment due to the resultant comorbidities considering possible side-effects promotion.• Thus, an increased awareness towards the disease management among patients and medical doctors is required for better management goals based on this real-world practice evidence.

US database study: burden and healthcare resource utilization in adults with systemic endemic mycoses and aspergillosis

2020 ◽  
Vol 9 (8) ◽  
pp. 573-584
Author(s):  
Anna Forsythe ◽  
Gareth Lewis ◽  
Robyn Jordan ◽  
George R Thompson
Keyword(s):  
Resource Utilization ◽  
Antifungal Therapy ◽  
Healthcare Resource ◽  
Burden Of Illness ◽  
Cross Sectional Study ◽  
Healthcare Resource Utilization ◽  
Transplant Recipients ◽  
Cross Sectional ◽  
Itraconazole Treatment ◽  
Endemic Mycoses

Aim: This study evaluated burden of illness in immunocompromised patients with systemic mycoses (SM) eligible for itraconazole treatment, specifically, histoplasmosis, blastomycosis and aspergillosis. Methods: A cross-sectional study used an electronic medical record network integrating information from 30 US hospitals, including >34 million patients, to evaluate burden and healthcare resource utilization over 6 months following initiation of antifungal therapy. Results: Symptomatic burden experienced by each of the otherwise healthy or age >65 or immunosuppressed cohorts receiving antifungal therapy for SM was comparable but significantly greater in cancer or HIV patients and transplant recipients. Across groups, there was substantially higher healthcare resource utilization in patients with SM versus matched controls without SM. Conclusion: The total impact of SM is particularly severe in high-risk or vulnerable populations.

Sign in / Sign up

Export Citation Format

Share Document